

May 25, 2022

Bozhou Rongjian Medical Appliance Co., Ltd. Wu Zhifang General Manager Jianghuai Supply Base, Zhongkai Group, Mengcheng County Bozhou, Anhui 233500 China

Re: K220578

Trade/Device Name: Transcutaneous Electrical Nerve Stimulator (Model RJTENS-1)

Regulation Number: 21 CFR 882.5890

Regulation Name: Transcutaneous Electrical Nerve Stimulator For Pain Relief

Regulatory Class: Class II

Product Code: GZJ

Dated: February 18, 2022 Received: February 28, 2022

Dear Wu Zhifang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Amber Ballard, PhD
Assistant Director
DHT5B: Division of Neuromodulation
and Physical Medicine Devices
OHT5: Office of Neurological
and Physical Medicine Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known)

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023

Expiration Date: 06/30/2023 See PRA Statement below.

K220578					
Device Name					
Transcutaneous Electrical Nerve Stimulator (Model RJTENS-1)					
Indications for Use (Describe) The Transcutaenous Electrical Nerve Stimulator (Model RJTENS-1) is an electrical nerve stimulator indicated for use for pain relief by applying an electrical current to electrodes on a patient's skin to treat pain. In particular, this device is indicated for use for symptomatic relief of chronic intractable pain and adjunctive treatment in the management of post surgical and post traumatic pain.					
Type of Use (Select one or both, as applicable)					
Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)					
CONTINUE ON A SEPARATE PAGE IF NEEDED.					

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary

[As required by 21 CFR 807.92]

1. Submission Information

510(k) Number: K220578

Date: April 25, 2022

Type of 510(k) Submission: Traditional 510(k)

Submitter/Manufacturer: Bozhou Rongjian Medical Appliance Co.,Ltd.

Jianghuai Supply Base, Zhongkai Group, Mengcheng County, Bozhou

City, 233500 Anhui, China

Contactor: Wu Zhifang

E-mail: doris.d@ceve.org.cn Tel: +86-558-7662968

2. Device Description

Proprietary Name: Transcutaneous Electrical Nerve Stimulator (Model RJTENS-1)

Common Name: TENS (Transcutaneous Electrical Nerve Stimulator)

Classification Name: Transcutaneous electrical nerve stimulator for pain relief

Product Code: GZJ
Device Class: 2

Regulation Number: 21 CFR 882.5890

Review Panel: Neurology

Indications for use: Transcutaneous Electrical Nerve Stimulator (Model RJTENS-1) is

an electrical nerve stimulator indicated for use for pain relief by applying an electrical current to electrodes on a patient's skin to treat pain. In particular, this device is indicated for use for symptomatic relief of chronic intractable pain and adjunctive treatment in the management of

post surgical and post traumatic pain.

Device Description: Transcutaneous Electrical Nerve Stimulator (Model RJTENS-1) sends

gentle electrical current to underlying nerves and muscle group via

electrodes applied on the skin to relieve pain.

The device has 16 programs (12 standard programs and 4 editable programs). It is a battery-powered portable device, comprising electronic stimulatory module and accessories of lead wires, electrodes and 4×1.5V

AAA alkaline batteries.

Two outlet sockets are used to connect skin electrodes by lead wires. The accessories of electrodes is 510(k) cleared device (K213879), Size:

50*50mm.

3. Predicate Device Identification

Predicate 510(k) Number: K202893 Marketing clearance date: June 18, 2021

Product name: Transcutaneous Electrical Nerve Stimulator
Manufacturer: Wuxi Jiajian Medical Instrument Co., Ltd

4. Substantially Equivalent Comparison Conclusion

Parameters	New Device	Predicate Device	Comparison			
510(k) Number	K220578	K202893				
	Transcutaneous Electrical					
Device Name	Nerve Stimulator (Model	Transcutaneous Electrical				
	RJTENS-1)	Nerve Stimulator				
M. C.	Bozhou Rongjian Medical	Wuxi Jiajian Medical				
Manufacturer	Appliance Co.,Ltd.	Instrument Co., Ltd				
	Transcutaneous Electrical Nerve	Transcutaneous Electrical				
	Stimulator ((Model RJTENS-1) is	Nerve Stimulator is an electrical				
	an electrical nerve stimulator	nerve stimulator indicated for				
	indicated for use for pain relief	use for pain relief by applying				
	by applying an electrical	an electrical current to				
	current to electrodes on a	electrodes on a patient's skin to				
Indication for Use	patient's skin to treat pain. In	•	Same			
	particular, this device is indicated	device is indicated for use for				
	for use for symptomatic relief of	symptomatic relief of chronic				
	chronic intractable pain and	intractable pain and adjunctive				
	adjunctive treatment in the	treatment in the management of				
	management of post surgical and	post surgical and post traumatic				
	post traumatic pain.	pain.				
Type of use	Prescription use	Prescription use	Same			
Power Source(s)	1.5Vx4 AAA alkaline battery	1.5Vx4 AAA alkaline battery	Same			
- Method of Line		-	Sume			
Current Isolation	N/A	N/A	Same			
- Patient Leakage						
Current						
- Normal						
Condition (µA)	2μΑ	2μΑ	Same			
- Single Fault						
Condition (µA)	NA	NA				
Average DC curren	<u> </u>					
through electrodes						
when device is on b	out <0.01μA	<0.01μΑ	Same			
no pulses are being	•	0.01611	Sume			
applied (µA)						
Number of program	n 16	16	Same			
Number of Output						
channels:	2	2	Same			
- Synchronous						
or Alternating?	Synchronous	Synchronous	Same			
- Method of						
Channel Isolation	By Transformer	By Transformer	Same			
Regulated Current	Regulated Current or					
Regulated Voltage?	Current control	Current control	Same			
Software/Firmware		Yes	Same			

Micropro	cessor				
Control?	000001				
Automatic Overload					
Trip?		No	No	Same	
Automatic No-Load					
Trip?		No	No	Same	
Automatic Shut Off?		Yes	Yes	Same	
User Override					
Control?		Yes	Yes	Same	
	On/Off Status?	Yes	Yes	Same	
Indicat or	Low Battery?	Yes	Yes	Same	
Display	Voltage/Cu rrent Level?	Yes	Yes	Same	
Timer Range (minutes)		10~90 min	10~90 min	Same	
Compliance with Voluntary Standards?		ANSI AAMI ES60601-1, IEC 60601-1-2, IEC 60601-2-10	ANSI AAMI ES60601-1, IEC 60601-1-2, IEC 60601-2-10	Same	
Compliance with 21 CFR 898?		Yes	Yes	Same	
Weight (grams)		Approx.96g without battery	Approx.96g without battery	Same	
Dimensions (mm) [W x H x D]		140*64*28 mm	140*64*28 mm	Same	
Housing Materials & Construction		ABS	ABS	Same	
Waveform		Monophasic	Monophasic	Same	
Shape		Rectangular pulse	Rectangular pulse	Same	
Maximum Output Voltage (volts)		30V±10% @500Ω	30V±20% @500Ω		
Maximum Output Current (specify units)		60mA±10% @500Ω	60mA±20% @500Ω	Similar	
Pulse wid	lth (µsec)	75-300μs±10%	75-300µs±20%	Note 1	
Pulse Per	riod (msec)	8.33-1000ms	8.33-1000ms		
Max. pulse frequency (Hz) [or Rate (pps)]		1-120Hz±10%	1-120Hz±20%		
Net Charge (μC per pulse)		0.65μC @500Ω	0.65μC @500Ω		
Maximu	n Phase			1	
Charge, (μC)		18μC @500Ω	18μC @500Ω	Same	
Maximum Average Current, (mA)		2.16mA @500Ω	2.16mA @500Ω		
Maximum Current		0.09mA/cm ² @500Ω	$0.09 \mathrm{mA/cm^2}$ @ 500Ω		

Density, (mA/cm ² ,			
r.m.s.)			
Maximum Average			
Power Density,	2.59mW/cm ² @500Ω	2.59mW/cm ² @500Ω	
(mW/cm ²)			
Accessories	Electrodes, cables, battery	Electrodes, cables, battery	Same

Comparison in details:

Note 1:

The deviation from the amplitude, frequency and pulse width of the proposed device are different from those of the predicate device. The proposed device has less deviation than the predicate device, which means that its output is more stable. And both the proposed device and predicate device passed ANSI AAMI ES60601-1, IEC 60601-1-2, IEC 60601-2-10 standards tests. Therefore, this difference will not raise any safety or effectiveness issue.

5. Non-Clinical Test Conclusion

Bench tests were conducted on Transcutaneous Electrical Nerve Stimulator (Model RJTENS-1) to verify that the proposed device met all design specifications as was Substantially Equivalent (SE) to the predicate device. The following tests were performed on the proposed device:

- ANSI AAMI ES60601-1: 2005/(R) 2012 And A1: 2012, C1: 2009/(R) 2012 And A2: 2010/(R) 2012 (Consolidated Text) Medical Electrical Equipment Part 1: General Requirements For Basic Safety And Essential Performance (IEC 60601-1: 2005, MOD);
- IEC 60601-2-10 Edition 2.1 2016-04, Medical Electrical Equipment Part 2-10: Particular Requirements For The Basic Safety And Essential Performance Of Nerve And Muscle Stimulators;
- IEC 60601-1-2 Edition 4.0 2014-02 Medical electrical equipment Part 1-2: General requirements for basic safety and essential performance Collateral Standard: Electromagnetic disturbances Requirements and tests;

6. Clinical Test

Clinical data was not including in this submission.

7. Conclusions

The conclusions drawn from the non-clinical tests demonstrate that the device is as safe, as effective, and performs as well as the legally marketed device identified in the submission. Thus the subject device is substantially equivalent to the predicate device.